VIRI News and Press, Virios Therapeutics Inc. From 05/05/22

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , announced today that its first quarter 2022 financial results wil...

- Top line Data from the FORTRESS Study Expected in September 2022 - Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including f...

Virios Therapeutics (NASDAQ:VIRI) has filed for a $150M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for general corporate purposes. The offering can include common stock, prefer...

Virios Therapeutics, Inc. (VIRI) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Angela Walsh – Senior Vice President-Finance and Treasurer Greg Duncan – Chief Executive Officer Ralph Grosswald – Senior Vice President-Operations Conference ...

Virios Therapeutics press release (NASDAQ:VIRI): Q4 GAAP EPS of -$0.54 beats by $0.29. Cash on hand of $14.0 million on December 31, 2021 For further details see: Virios Therapeutics GAAP EPS of -$0.54 beats by $0.29

- Top line Data from Phase 2b FORTRESS Study of IMC-1 on Track for Q3 2022 - - Pipeline Expanded with IMC-2 as Treatment for Long COVID to be Evaluated in New Exploratory Study Targeted to Commence in Q2 2022 - - Conference Call Today at 8:30 a.m. ET - Viri...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia , announced today that its fourth quarter and full year 2021 financial results will be report...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia , announced today that Greg Duncan, Chairman and Chief Executive Officer, will participate in...

Long COVID Impacts Up To 30% of COVID-19 Patients Activation of Dormant Herpes Virus Infections are Hypothesized as a Potential Trigger of Long COVID Combination Therapy with IMC-2 (valacyclovir and celecoxib) Expands Virios’ Pipeline Virios Therapeutics, In...

ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, ...